Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Comparison of VxWave and Standard Ultrasound Measurements of Blood Vessels in the Arm

29 ottobre 2026 aggiornato da: Vexev Pty Ltd

The VxWave Ultrasound Imaging System Upper Limb Clinical Performance Trial

This study compares blood-vessel measurements obtained with the VxWave Ultrasound Imaging System and a standard ultrasound system operated by a qualified sonographer. Adults aged 21 years or older undergo scanning of the same arm with both systems at one study visit. The researchers compare vessel diameter and blood-flow velocity at three specified locations in the upper arm and forearm. They also assess scan completion, scanning time, participant comfort, device deficiencies and adverse events. A subset undergoes a repeat standard ultrasound scan to assess the repeatability of the reference measurements.

Panoramica dello studio

Descrizione dettagliata

This is an interventional, single-cohort, within-participant paired method-comparison study. Every participant undergoes VxWave scanning first, followed by Philips Lumify scanning of the same arm by a qualified vascular sonographer in a separate room. Three locations are examined: the brachial artery immediately proximal and immediately distal to the midpoint between the elbow crease and axillary fold, and the radial artery at the midpoint between the radial styloid process and elbow crease.

A qualified vascular sonographer who did not acquire the images performs all measurements offline using OsiriX MD for Lumify images and VxView for VxWave images. Random dataset identifiers conceal participant identity, pairing and repeat status. Measurements from the corresponding other-system dataset are unavailable during review. Imaging-system identity is not concealed by the use of separate software platforms.

The first 20 consecutive participants after Participant ID 030 who complete comparator acquisition undergo one repeat comparator scan after probe and gel removal and at least two minutes of rest. The first comparator acquisition remains the reference for primary agreement analysis; repeat acquisition is used only for reference-pathway repeatability.

Enrollment stops upon reaching either 50 participants with successful unilateral scans in the per-protocol set or 85 participants in the full analysis set. The first unilateral visit supplies the primary participant record. Optional contralateral-arm visits provide exploratory observations. No routine follow-up visit is scheduled; any adverse event is followed until resolution or 60 days, whichever occurs first.

Participants may provide consent and enroll at Prince of Wales Private or remotely. All ultrasound scanning and study imaging data acquisition are performed at Vexev Pty Ltd, Suite 501, 78 Kippax Street, Surry Hills NSW 2010. The Prince of Wales Private location is used for recruitment, consent and enrollment only; no scanning or imaging data acquisition takes place there.

Tipo di studio

Interventistico

Iscrizione (Stimato)

85

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Michael Cartmill
  • Numero di telefono: +61 400 223 656
  • Email: michael@vexev.com

Luoghi di studio

    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Prince of Wales Private, A/Prof Shannon Thomas's Rooms (Recruitment and Enrollment Only)
        • Contatto:
      • Surry Hills, New South Wales, Australia, 2010
        • Vexev Pty Ltd
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

21 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 21 years or older and able to provide written informed consent.
  • Complete upper limb(s).

Exclusion Criteria:

  • Unable to provide informed consent.
  • Unable or unwilling to place the limb onto the VxWave scanning bed.
  • Infection risk to site staff and/or other study participants.
  • Open or healing wound on the study limb.
  • Known abnormal upper-limb vascular anatomy that would make scanning at the protocol discrete locations infeasible.
  • Known allergy to parabens present in standard ultrasound gels.
  • Any other reason at the discretion of the Principal Investigator.
  • Previous upper-limb vascular surgery.
  • Highly dependent on medical care.
  • Cognitive impairment or intellectual disability.

Vascular-anatomy and prior-surgery exclusions are assessed using self-reported history; review of medical records is not required for this assessment.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: VxWave and Comparator Ultrasound

All participants undergo VxWave scanning followed by Philips Lumify scanning of the same arm during one study visit. The first 20 consecutive participants after Participant ID 030 who complete comparator acquisition also undergo a repeat Lumify scan after probe lift-off and at least two minutes of rest.

Robotically controlled acquisition of duplex B-mode and Doppler ultrasound data of the upper-limb vasculature, excluding the hand. The participant rests the limb on the scan bed while the probe moves beneath it. Images are measured offline using VxView. VxWave scanning occurs before the comparator scan.

Qualified vascular-sonographer acquisition of ultrasound data from the same upper-limb vascular locations after VxWave scanning. Images are measured offline using OsiriX MD. The specified repeatability subset undergoes a separate repeat comparator acquisition after probe lift-off and at least two minutes of rest.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Inter-System Agreement in Arterial Diameter
Lasso di tempo: During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).

Mean bias and 95% limits of agreement for VxWave minus comparator arterial diameter in millimetres at three pre-specified brachial/radial artery locations. Each location uses the mean of three diameter measurements. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals for bias and limits of agreement. The +/-0.5 mm margin is a descriptive benchmark and does not define a binary study-success criterion. Only diagnostic-quality measurements are included in agreement analysis.

During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).
Inter-System Agreement in Peak Systolic Velocity
Lasso di tempo: During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).

Mean percentage bias and 95% limits of agreement in symmetric relative percentage differences between VxWave and comparator peak systolic velocity at the three pre-specified brachial/radial artery locations. Mean of three representative peak systolic velocity measurements per location. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals for bias and limits of agreement. Absolute-scale agreement in cm/s is a sensitivity analysis. No PSV acceptance criterion is specified. Only diagnostic-quality measurements are included.

During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Successful VxWave Scan Completion
Lasso di tempo: During the VxWave scan at the first study visit (Day 1).

Percentage of participants for whom VxWave completes the peripheral vascular imaging examination, with scan data judged by the reporting sonographer to be of diagnostic quality for measurement and able to confirm measurements. Reasons for failure include inability to perform both B-mode and Doppler measurements at two of the three discrete locations, or failure to complete scan data acquisition within a reasonable time (less than 55 minutes).

During the VxWave scan at the first study visit (Day 1).
Time Required to Complete VxWave Scanning
Lasso di tempo: During the VxWave scan at the first study visit (Day 1).

Elapsed time in minutes from initiation of the first acquisition run on the VxWave console to scan status complete on the final acquisition run, including time between runs. A scan may contain more than one acquisition run, including restarts after participant repositioning.

During the VxWave scan at the first study visit (Day 1).
Participant Comfort and Satisfaction With VxWave Scanning
Lasso di tempo: Immediately after the VxWave scan during the first study visit (Day 1).

Four questionnaire items assess overall comfort, satisfaction with scanning time, satisfaction with audible noise and overall satisfaction. Each item has five ordered response categories: Excellent, Very good, Good, Fair and Poor, with Excellent representing the most favorable response. Ordinal responses will be summarised using median/interquartile range or proportions. No composite score is specified in the protocol or supplied assessment form.

Immediately after the VxWave scan during the first study visit (Day 1).
Repeatability of Comparator Arterial Diameter Measurements
Lasso di tempo: During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.

For the first 20 consecutive participants after Participant ID 030 who complete comparator acquisition, assess mean difference (bias), 95% limits of agreement and repeatability coefficient between first and repeat comparator arterial diameter measurements in millimetres at each pre-specified location. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals for bias and limits of agreement. The first comparator acquisition remains the reference for the primary endpoint; repeat acquisition is used for this secondary endpoint only.

During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.
Repeatability of Comparator Peak Systolic Velocity Measurements
Lasso di tempo: During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.

For the same 20-participant repeatability cohort, assess mean difference (bias), 95% limits of agreement and repeatability coefficient between first and repeat comparator peak systolic velocity measurements, expressed as symmetric relative percentage differences, at each pre-specified location. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals. This descriptive endpoint characterises reference-pathway repeatability and does not define an acceptance test.

During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Scanned Participants With at Least One Device Deficiency
Lasso di tempo: During the study scanning visit (Day 1).

100 multiplied by the number of unique scanned participants whose scan is associated with at least one VxWave device deficiency, divided by the total number of unique participants who undergo a scan. Include attempted scans regardless of successful completion or diagnostic image quality. Each participant is counted once, even if more than one deficiency or scan occurs. Device deficiencies include those identified before scan completion.

During the study scanning visit (Day 1).
Percentage of Scanned Participants With at Least One Adverse Event
Lasso di tempo: During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.

100 multiplied by the number of unique scanned participants who experience at least one adverse event (AE), divided by the total number of unique participants who undergo a scan. AEs are counted regardless of their relationship to the device or study procedure. Include attempted scans regardless of successful completion. Each participant is counted once, even if multiple AEs or scans occur. Device/procedure-related AEs are included in this overall AE measure and are also reported separately as adverse device effects.

During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.
Percentage of Scanned Participants With at Least One Adverse Device Effect
Lasso di tempo: During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.

100 multiplied by the number of unique scanned participants who experience at least one adverse device effect (ADE), divided by the total number of unique participants who undergo a scan. Per the protocol, an ADE is an AE related to the VxWave Ultrasound Imaging System or study procedure. Include attempted scans regardless of successful completion. Each participant is counted once, even if multiple ADEs or scans occur. ADEs are a subset of all AEs; the overall AE percentage and ADE percentage must not be added together.

During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Tam Nguyen, Vexev Pty Ltd

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

15 gennaio 2027

Completamento dello studio (Stimato)

20 gennaio 2027

Date di iscrizione allo studio

Primo inviato

29 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

29 ottobre 2026

Primo Inserito (Effettivo)

4 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

4 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CIP-2

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Individual participant data will be shared on request.

Criteri di accesso alla condivisione IPD

On request.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi